18 results
10-K
2023 FY
NMRA
Neumora Therapeutics Inc.
7 Mar 24
Annual report
4:05pm
of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events
424B4
NMRA
Neumora Therapeutics Inc.
18 Sep 23
Prospectus supplement with pricing info
4:12pm
if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well
S-1/A
NMRA
Neumora Therapeutics Inc.
11 Sep 23
IPO registration (amended)
6:07am
more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials
S-1
EX-10.17
NMRA
Neumora Therapeutics Inc.
25 Aug 23
IPO registration
5:03pm
, commissions and/or benefits are due to Executive, except as provided in this Agreement, (c) Executive has no known workplace injuries or occupational
S-1
EX-10.5
5i2tu
25 Aug 23
IPO registration
5:03pm
S-1
w3hiuw4pv wrwjm3jww9
25 Aug 23
IPO registration
5:03pm
DRS/A
EX-10.18
8cau58p
9 Aug 23
Draft registration statement (amended)
12:00am
DRS/A
xyew40ng7duaxgr4txn9
9 Aug 23
Draft registration statement (amended)
12:00am
DRS/A
zu8eju j6xv4
30 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
ykl ddwuutbje4l
2 May 23
Draft registration statement (amended)
12:00am
DRS/A
2sqfix9w jedjoq4
2 Sep 22
Draft registration statement (amended)
12:00am
DRS/A
tbmji9yyj6chwf48x
10 Jun 22
Draft registration statement (amended)
12:00am
DRS/A
yp6th067n11yrn3 2z
2 May 22
Draft registration statement (amended)
12:00am
DRS/A
EX-10.23
w9bh43f1pk
2 May 22
Draft registration statement (amended)
12:00am
DRS/A
oznay
23 Dec 21
Draft registration statement (amended)
12:00am
DRS/A
EX-10.5
iuac5nh8iyli akcoj
23 Dec 21
Draft registration statement (amended)
12:00am
DRS
7cin72lbvh63cx
8 Nov 21
Draft registration statement
12:00am
- Prev
- 1
- Next